This HTML5 document contains 91 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00750/identifier/wikipedia/
n22http://linked.opendata.cz/resource/AHFS/
n24http://linked.opendata.cz/resource/drugbank/company/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00750/identifier/pharmgkb/
n26http://linked.opendata.cz/resource/drugbank/dosage/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00750/identifier/kegg-compound/
n23http://linked.opendata.cz/resource/drugbank/mixture/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00750/identifier/bindingdb/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00750/identifier/pubchem-compound/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00750/identifier/pubchem-substance/
n8http://bio2rdf.org/drugbank:
n14http://linked.opendata.cz/resource/drugbank/drug/DB00750/identifier/kegg-drug/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00750/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n18http://linked.opendata.cz/resource/drugbank/drug/DB00750/identifier/national-drug-code-directory/
n6http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n27http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00750/identifier/chemspider/
xsdhhttp://www.w3.org/2001/XMLSchema#
n10http://linked.opendata.cz/resource/drugbank/drug/DB00750/identifier/chebi/
n25http://linked.opendata.cz/resource/atc/
n21http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00750
rdf:type
n3:Drug
n3:description
A local anesthetic that is similar pharmacologically to lidocaine. Currently, it is used most often for infiltration anesthesia in dentistry. (From AMA Drug Evaluations Annual, 1992, p165)
n3:dosage
n26:271B57B1-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:indication
Used as a local anaesthetic and is often used in dentistry.
owl:sameAs
n6:DB00750 n8:DB00750
dcterms:title
Prilocaine
adms:identifier
n10:8404 n11:4737 n12:50017654 n13:C07531 n14:D00553 n15:DB00750 n16:4906 n17:46505066 n18:66312-520-14 n19:PA451101 n20:Prilocaine
n3:mechanismOfAction
Prilocaine acts on sodium channels on the neuronal cell membrane, limiting the spread of seizure activity and reducing seizure propagation. The antiarrhythmic actions are mediated through effects on sodium channels in Purkinje fibers.
n3:packager
n24:271B57AE-363D-11E5-9242-09173F13E4C5 n24:271B57AF-363D-11E5-9242-09173F13E4C5 n24:271B57AC-363D-11E5-9242-09173F13E4C5 n24:271B57AD-363D-11E5-9242-09173F13E4C5 n24:271B57AA-363D-11E5-9242-09173F13E4C5 n24:271B57AB-363D-11E5-9242-09173F13E4C5 n24:271B57A8-363D-11E5-9242-09173F13E4C5 n24:271B57A9-363D-11E5-9242-09173F13E4C5 n24:271B57A6-363D-11E5-9242-09173F13E4C5 n24:271B57A7-363D-11E5-9242-09173F13E4C5 n24:271B57A4-363D-11E5-9242-09173F13E4C5 n24:271B57A5-363D-11E5-9242-09173F13E4C5 n24:271B57A2-363D-11E5-9242-09173F13E4C5 n24:271B57A3-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Prilocaine is metabolized in both the liver and the kidney and excreted via the kidney.
n3:synonym
2-(Propylamino)-O-propionotoluidide alpha-N-Propylamino-2-methylpropionanilide Prilocaïne N-(2-Methylphenyl)-2-(propylamino)propanamide O-Methyl-alpha-propylaminopropionanilide Propitocaine Prilocain Prilocainum 2-Methyl-alpha-propylaminopropionanilide Prilocaine base O-Methyl-2-propylaminopropionanilide Prilocaina
n21:hasAHFSCode
n22:72-00-00
n3:mixture
n23:271B579F-363D-11E5-9242-09173F13E4C5 n23:271B57A0-363D-11E5-9242-09173F13E4C5 n23:271B579D-363D-11E5-9242-09173F13E4C5 n23:271B579E-363D-11E5-9242-09173F13E4C5 n23:271B57A1-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
98%
n3:salt
n3:synthesisReference
"DrugSyn.org":http://www.drugsyn.org/Prilocaine.htm
n3:IUPAC-Name
n4:271B57B6-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B57BC-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B57BB-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B57B8-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B57B9-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B57BA-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B57B4-363D-11E5-9242-09173F13E4C5 n4:271B57CC-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B57B5-363D-11E5-9242-09173F13E4C5 n4:271B57CF-363D-11E5-9242-09173F13E4C5 n4:271B57B2-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B57B3-363D-11E5-9242-09173F13E4C5
n21:hasATCCode
n25:N01BB04
n3:H-Bond-Acceptor-Count
n4:271B57C2-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B57C3-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B57BD-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B57BE-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B57C0-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B57BF-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B57C1-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
721-50-6
n3:category
n3:containedIn
n27:271B57B0-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B57C8-363D-11E5-9242-09173F13E4C5
n3:Boiling-Point
n4:271B57CE-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B57CA-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B57CB-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B57CD-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B57C7-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B57C6-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B57C9-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B57B7-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B57C4-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B57C5-363D-11E5-9242-09173F13E4C5